An antiretroviral regimen based on lamivudine +stavudine+protease inhibitor impairs peripheral fat accrual in HIV-infected children and adolescents. We assess the effect on body composition parameters of replacing stavudine with tenofovir and protease inhibitor with efavirenz in paediatric patients.
Methods
A 96-week prospective study on 24 patients, (age range: 5.0–17.9 years) with stable undetectable HIV-1 loads, who were switched from stavudine to tenofovir and from protease inhibitor to efavirenz. Patient assessment included: body composition parameters measured by dual-energy X-ray absorptiometry (DXA), viral load and CD4+ T-count and percentage. As a control group for DXA data, we studied 143 healthy controls (HCs; age range: 4.9–20.0 years).
Results
Virological suppression and unchanged CD4+T-cell count and percentage were maintained in all patients. At baseline, patients showed decreased total, arm and leg fat masses (P<0.01) but a similar trunk fat mass to HCs. From baseline to week 96, patient fat mass increases were comparable to those for HCs (total fat: 1.3 vs 1.2 kg; fat in arms: 0.09 vs 0.08 kg; fat in legs: 0.5 vs 0.5 kg; trunk fat: 0.6 vs 0.6 kg). However, at week 96, total and leg fat mass in patients were still significantly lower than those in HCs (P<0.02). At baseline and at week 96, lean mass in patients was similar to that expected in HCs.
Conclusions
Replacing stavudine with tenofovir and protease inhibitor with efavirenz for 96 weeks in lipoatrophic paediatrics patients led to a restoration of physiological fat accrual. Lipoatrophy did not progress but was still present, indicating the need for additional strategies.
References
1.
TaylorP., WorrellC., SteinbergS.M.Natural history of lipid abnormalities and fat redistribution among human immunodeficiency virus-infected children receiving long-term, protease inhibitor-containing, highly active antiretroviral therapy regimens.Pediatrics2004; 114: e235–e242.
2.
European Paediatric Lipodistrophy Group.Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe.AIDS2004; 18: 1443–1451.
3.
BeregszasziM., DollfusC., LevineM.Longitudinal evaluation and risk factor of lipodystrophy and associated metabolic changes in HIV-infected children.J Acquir Immune Defic Syndr2005; 40: 161–168.
4.
BrambillaP., BricalliD., SalaN.Highly active anti-retroviral-treated HIV-infected children show fat distribution changes even in absence of lipodystrophy.AIDS2001; 15: 2415–2422.
5.
LichtensteinK.A.Redefining lipodystrophy syndrome. Risk and impact on clinical decision making.J Acquir Immune Defic Syndr2005; 39: 395–400.
6.
ViganòA., MoraM., TestolinC.Increased lipodystrophy is associated with increased exposure to highly active antiretroviral therapy in HIV-infected children.J Acquir Immune Defic Syndr2003; 32: 482–489.
7.
CarrA., WorkmanC., SmithD.E.for Mitochondrial Toxicity Study Group. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy.J Am Med Assoc2002; 288: 207–215.
8.
JohnM., McKinnonE.J., JamesI.R.Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.J Acquir Immune Defic Syndr2003; 33: 29–33.
9.
MartinA., SmithD.E., CarrA.for the Mitochondrial Toxicity (MITOX) Study Group. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.AIDS2004; 18: 1029–1036.
10.
MoyleG., SabinC., CartledgeJ. & the Rave Study Group. A 48-week, randomized, open-label comparative study of tenofovir DF vs abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 22–25 February 2005. Abstract 44LB.
11.
GallantJ.E., StaszewskiS., PozniakA.L.for the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients. A 3-year randomized trial.J Am Med Assoc2004; 292: 191–201.
12.
ViganòA., AldrovandiG.M., GiacometV.Improvement in dyslipidaemia after switching stavudine to tenofovir and replacing protease inhibitors with efavirenz in HIV-infected children.Antiv Ther2005; 10: 917–924.
TannerJ.M., WhitehouseR.H.Clinical longitudinal standards for height, weight, height velocity and weight velocity and stages of puberty.Arch Dis Child1976; 51: 170–179.
15.
BrambillaP., BosioL., ManzoniP., PietrobelliA., BeccariaL., ChiumelloG.Peculiar body composition in patients with Prader-Labhart-Willi sindrome.Am J Clin Nutr1997; 65: 1369–1374.
16.
CacciariE., MilaniS., BalsamoA.Italian cross-sectional growth charts for height, weight and BMI (6–20 y).Eur J Clin Nutr2002; 56: 171–180.
17.
FomonS.J., HaschkeF., ZieglerE.E., NelsonS.E.Body composition of reference children from birth to age 10 years.Am J Clin Nutr1982; 35: 1169–1175.
18.
HaschkeF.Body composition during adolescence. In Body Composition Measurements in Infants and Children1999; pp. 76–83. Edited by KlishW.J., & KretchmerN.. Columbus, OH: Ross Laboratories.
19.
EllisK.J., ShypailoR.J., AbramsS.A., WongW.W.The reference child and adolescent models of body composition. A contemporary comparison.Ann NY Acad Sci2000; 904: 374–382.
20.
Rolland-CacheraM.F.Body composition during adolescence: methods, limitations and determinants.Horm Res1993; 39Suppl 3: 25–40.
21.
SiervogelR.M., MaynardM., WisemandleW.A.Annual changes in total body fat and fat-free mass in children from 8 to 18 years in relation to changes in body mass index. The Fels Longitudinal Study.Ann NY Acad Sci2000; 904: 420–423.
22.
EllisK.J., ShypailoR.J., PrattJ.A.Accuracy of dual-energy X-ray absorptiometry for body-composition measurements in children.Am J Clin Nutr1994; 60: 660–665.
23.
LocknerD.W., HeywardV.H., BaumgartnerR.N., JenkinsK.A.Comparison of air-displacement plethysmography, hydrodensitometry, and dual X-ray absorptiometry for assessing body composition of children 10 to 18 years of age.Ann NY Acad Sci2000; 904: 72–78.
24.
GoranM.I., BallG.D.C., CruzM.L.Obesity and risk of type 2 diabetes and cardiovascular disease in children and adolescents.J Clin Endocrinol Metab2003; 88: 1417–1427.
25.
DesprésJ.P., AllardC., TremblayA., TalbotJ., BouchardC.Evidence for a regional component of body fatness in the association with serum lipids in men and women.Metabolism1985; 34: 967–973.
26.
FrischR.E.Body fat, menarche, fitness and fertility.Hum Reprod1987; 2: 521–533.
27.
BakerE.R.Body weight and the initiation of puberty.Clin Obstet Gynecol1985; 28: 573–579.
28.
SiervogelR.M., DemerathE.W., SchubertC.Puberty and body composition.Horm Res2003; 60Suppl 1: 36–45.
29.
DaviesM.J.Evidence for effects of weight on reproduction in women.Reprod Biomed Online2006; 12: 552–561.
30.
SwenneI.Weight requirements for return of menstruations in teenage girls with eating disorders, weight loss and secondary amenorrhoea.Acta Paediatr2004; 93: 1449–1455.
31.
GrinspoonS., CorcoranC., MillerK.Body composition and endocrine function in women with acquired immunodeficiency syndrome wasting.J Clin Endocrinol Metab1997; 82: 1332–1337.
32.
BuchaczK., RogolA.D., LindseyJ.C., Pediatric AIDS Clinical Trials Group 219 Study Team. Delayed onset of pubertal development in children and adolescents with perinatally acquired HIV infection.J Acquir Immune Defic Syndr2003; 33: 56–65.
33.
MahoneyE.M., DonfieldS.M., HowardC., KaufmanF., GertnerJ.M.HIV-associated immune dysfunction and delayed pubertal development in a cohort of young hemophiliacs. Hemophilia Growth and Development Study.J Acquir Immune Defic Syndr1999; 21: 333–337.
